GlassScriptPhysician profile
George C Li
NPI 1952398562
$3,887.62
in general payments reported to CMS, 2019-2025
29 companies · $689 in 2025
The $689 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $58.97 · 2021: $414 · 2022: $734 · 2023: $659 · 2024: $1,060 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,109.35 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Dragonfly Opstar |
| Novartis Pharmaceuticals Corporation | $487.02 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $226.46 | 2020-2022 | |
| Pfizer INC. | $217.95 | 2019-2024 | |
| Amgen INC. | $214.59 | 2019-2025 | Repatha |
| Medtronic, INC. | $196.33 | 2023-2024 | Hawkone, Endurant Iis |
| E.R. Squibb & Sons, L.L.C. | $195.29 | 2021-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $159.11 | 2020-2025 | Farxiga, Lokelma |
| Boston Scientific Corporation | $152.56 | 2024-2025 | Accolade Sr, General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| Acutus Medical, INC. | $134.64 | 2019 | |
| Heartflow, INC. | $100.49 | 2019-2021 | |
| Esperion Therapeutics, INC. | $99.04 | 2022-2025 | Nexletol |
| Novo Nordisk INC | $93.74 | 2024-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.07 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $62.46 | 2022-2023 | Verquvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $60.02 | 2024 | Flexitouch Plus, Entre Plus |
| Kiniksa Pharmaceuticals International, Plc | $55.34 | 2024 | Arcalyst |
| Cvrx, INC. | $50.81 | 2024-2025 | Barostim Neo System |
| Altathera Pharmaceuticals LLC | $24.11 | 2022 | |
| Lilly USA, LLC | $19.12 | 2025 | Zepbound |
| Sanofi-Aventis U.S. LLC | $18.67 | 2021 | |
| Glaxosmithkline, LLC. | $17.17 | 2025 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $16.64 | 2019 | |
| Irhythm Technologies, INC. | $16.63 | 2024 | Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $15.67 | 2024 | |
| Biosense Webster, INC. | $15.61 | 2023 | Carto 3 |
| Ge Healthcare | $14.53 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $13.85 | 2023 | Arcalyst |
| Cardiva Medical, INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.